e-mail Hillary if you can and mention orphan drug price problems and how HZNP is taking advantage of poor patients.
Some greedy companies like HZNP is taking advantage of orphan drugs unfairly and putting pressure on the system.
5 million shares but only if the price goes below $10.
May 10 (Reuters) - The U.S. Attorney's Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings.
Federal prosecutors have approached at least three companies, including Johnson & Johnson, Merck & Co and Endo International Plc, demanding information about their contracts with pharmacy benefit managers.
Pharmacy benefit managers, or PBMs, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications.
When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing.
J&J said in a regulatory filing on Tuesday it had received a "civil investigative demand," seeking information about its contractual relationships with pharmacy benefit managers over some of its products from early 2006 through the present.
If your claim of 45% is true then it puts your bases around $10.13. This is the price from June 2014 if you didn't trade it to bring your cost down.
If you had the stock since 2014 then why didn't you sell at $38 or even at prices above $30.
Something does not add up in your case.
Anyway, most people posting here have bases between $13 to $25. Even ginger sold around $25 before plummeted below $20.
What are you looking for in this stock.
I bought HZNP around $4 and I was happy to exit above $10. I made good money in the stock but as people say, you have to read both side of newspaper.
The only thing went up were costs and they went up significantly. Still, R&D was at minimum, less than 4% of revenue. This is not a growth company but a roll-over.
Duexis and Vimovo declined almost 51% and 45.7% sequentially to $29.6 million and $25.5 million, and Lodotra revenues plummeted 33% because increased control by certain pharmacy benefit managers and payors. Orphan and other drugs almost flat compare to previous quarter in spite of almost 10% price increase, adding many salesmen and addition of Crytexxa. Revenue missed big time and expenses went up sharply.
If this trend continues then HZNP is doomed and I thing it is the end of Duexis and Vimovo.
Now, there is nothing to support the shares after investors are back to reality.
alkhan, you seem to be desperate for anything that removes attention from tomorrow's earnings report.
HZNP does not have cash or financing power to go after DEPO anymore. Paying with shares, this has been the main problem in the first place anyway. Unfortunately, HZNP has vaporized both its cash and its share price and it is a tiger with no teeth. There will be another company that will grab DEPO while HZNP is watching.
Yes, DEPO needs a cash deal. Unfortunately, HZNP does not have cash or financing power to do it. It is too late for HZNP to issue shares to get $3 billions.
This is positive for DEPO but it won't help HZNP at all since HZNP is in much weaker position now.
HZNP is trading below DEPO and it wasted $510m of its cash on Crystexxa. TW was impatient and he was not thinking clearly after he lost DEPO.
Wall Street has new reason to believe that a dead pharma deal will come back to life.
Despite being rebuffed last year, Horizon Pharma executives have raised hopes that they will take another run at smaller rival Depomed if that company is forced to put itself up for sale, sources said.
“They say, ‘Right now we are passive, but if the asset were put into play we would be active participants,’” one large Depomed shareholder told The Post.
A Horizon spokesman denied the company had spoken to Depomed shareholders but said: “If the Depomed board chose to offer Depomed for sale, and invited Horizon to participate in the bidding, Horizon would evaluate the opportunity anew, as it would any potential acquisition.”
Depomed, which makes pain treatments among other products, successfully beat back a $3 billion hostile bid from Horizon in November.
Last week, Depomed settled a lawsuit that had scuttled Horizon’s pursuit of the company. As part of the settlement, Horizon agreed not to initiate another unsolicited takeover of the Depomed until 2020.
Now, activist investor Starboard, which owns nearly 10 percent of Depomed, has launched a proxy fight to shake up the board and put the company in play again. Starboard has a month to call a special shareholder meeting. Assuming it succeeds, a sale process could follow.
To defend itself, Depomed has hired proxy adviser Innisfree and plans to meet with shareholders to present its case, sources said. Depomed declined to comment.
Horizon’s share price has fallen from $38 in July to $13.41, making a stock deal unattractive. But Horizon may be willing to offer cash this time around, sources said.
With or without insurance does not matter and the total cost to system matters.
If HZNP gives discounts to a small number of patients and then charges insurance and many other patients with a high price tag then this is a wrong policy.